Tuesday's broad market is barely moving, which makes the earnings winners easier to see. Cardinal Health and Aramark are both up roughly 8% in the latest reliably verified early-session snapshot, while strength in other drug distributors adds some sector confirmation to Cardinal's move.

The important distinction from Monday's energy rally is that oil itself has already reversed part of its morning surge. Today's cleaner momentum is coming from companies that changed the earnings or guidance picture rather than simply following a commodity headline.

Market snapshot

Prepared Tuesday, August 11, 2026, at approximately 3:15 p.m. BST / 10:15 a.m. ET. The latest reliably verified AP market snapshot used for index and headline stock moves was 9:35 a.m. ET, so these are intraday readings and can change before the close.

  • The S&P 500 was flat, the Dow was up 0.2%, and the Nasdaq was down 0.1%.
  • The U.S. 10-year Treasury yield had eased to 4.68% from 4.72% late Monday.
  • Brent crude briefly traded above $90 before pulling back to about $87.18, down 0.6% from Monday's settlement in AP's snapshot.
  • Cardinal Health was up 8.1% and Aramark 8.3% after their quarterly updates.
  • Wednesday's July CPI report is the main near-term macro risk; economists cited by AP expect annual inflation around 3.4%, down from 3.5% in June.

1. Cardinal Health: guidance matters more than the revenue miss

Cardinal Health has the strongest combination of price confirmation and forward evidence in today's non-tech tape.

Catalyst: The drug distributor forecast fiscal 2027 adjusted earnings of $12.40–$12.60 per share, above the roughly $12.04 analyst consensus reported by Reuters, after quarterly adjusted EPS of $2.91 beat the $2.42 estimate.

Evidence: Reuters reported Pharmaceutical and Specialty Solutions sales rose 6% to $55.4 billion, helped by branded and specialty-drug demand. The company also plans about $1 billion of share repurchases in fiscal 2027. AP had the stock up 8.1% shortly after the open.

The quarter was not perfect: total revenue of $63.67 billion missed the roughly $65.03 billion LSEG consensus. That is why the move is more interesting than a simple headline beat. Buyers appear to be giving more weight to the future profit outlook than to the top-line miss.

Main risk: If the earnings improvement depends too heavily on mix, temporary items or specialty-drug economics that later soften, today's valuation reset can unwind quickly. Drug distribution also carries regulatory, reimbursement and customer-concentration risk.

Invalidation: The momentum thesis weakens if Cardinal gives back most of the earnings gap while analysts cut the new fiscal-2027 profit expectations or the specialty segment loses its growth trajectory.

2. Aramark: a clean earnings reaction in a flat index

Aramark is today's other clear non-tech winner. AP reported the food and facilities-management company up 8.3% after it delivered stronger quarterly profit and revenue than analysts expected.

Catalyst: The immediate driver is the quarterly beat. It also follows a period in which Aramark had already been pointing to broad-based new-business growth and stronger base-business trends across its food and facilities operations.

Evidence: An 8% move while the S&P 500 is flat is meaningful relative strength. Unlike an oil producer moving with crude or a bank moving with yields, Aramark's move is tied primarily to company-specific operating evidence.

Main risk: Food and facilities services remain exposed to wage inflation, food costs, contract pricing and client retention. A strong quarter can be overwhelmed if margins fail to keep pace with revenue growth.

Invalidation: A rapid loss of most of today's earnings gap, especially alongside weaker margin or forward-growth commentary, would suggest the first reaction was relief rather than durable repricing.

3. Drug distributors: Cardinal is not moving completely alone

Cardinal's move has a useful second layer: other large U.S. drug distributors were also firm. Investor's Business Daily reported McKesson up about 2% and Cencora up nearly 2% in its Tuesday read, with both companies coming off recent quarters showing earnings growth.

That does not make the whole group equally attractive, but it matters. A company-specific 8% gap is more credible when economically related peers are also attracting buyers rather than falling sharply against it.

Catalyst: Continued demand for specialty medicines, oncology products, biosimilars and GLP-1-related distribution can support the group's earnings base if volumes and margins hold.

Evidence: Cardinal's raised profit outlook is being accompanied by positive peer price action rather than an isolated squeeze.

Main risk: This is a low-margin distribution industry. Reimbursement changes, manufacturer/customer concentration, regulation or a mix shift can change earnings expectations quickly.

Invalidation: The broader confirmation disappears if McKesson and Cencora reverse while Cardinal loses its gap, particularly if the weakness follows estimate cuts rather than a general market selloff.

Why I am not chasing Monday's oil winners here

Energy was Monday's obvious leader: Chevron, Exxon, ConocoPhillips, Occidental and refiners all jumped as crude rose. Tuesday morning, however, AP reported major U.S. oil shares close to unchanged while Brent had already swung from above $90 back toward $87.

That does not make the energy thesis bearish. It means today's momentum signal is less clean. The same geopolitical headline can move oil several dollars in either direction, so an energy trade currently carries unusually high event risk.

For this scan, earnings-backed strength in Cardinal Health and Aramark is easier to attribute and easier to invalidate than another bet on the next Iran/Hormuz headline.

What to watch next

The first test is simple: how much of the earnings gap survives the close? A stock that remains 6%–8% higher while the index stays flat is showing stronger demand than one that fades back into its prior range.

The second test arrives Wednesday with CPI. A hotter-than-expected inflation report could push Treasury yields higher and pressure the whole market. Cardinal and Aramark do not need a rising index to remain relative leaders, but a macro shock can still overwhelm company-specific momentum for a session.

The cleaner continuation signal would be both stocks holding most of today's gains while forward estimates move higher over the next several days.

Educational disclaimer: This article is for informational and educational purposes only. It is not financial advice, investment research or a recommendation to buy or sell any security. The market prices and percentage moves above are intraday observations from August 11, 2026 and can change materially before the U.S. close.

Sources

MarketMomentumInvestingCardinalHealthAramarkHealthcareStocks
Written and reviewed by /lico

Just writing down my thoughts, interests, and the things I learn along the way.